A lthough CD4 + regulatory T cells (Tregs) have received considerably more attention (1), CD8 + Tregs have been identified both as naturally occurring cells and after different immunotherapy regimen in various pathophysiological situations (2). In organ transplantation, CD8 + Tregs have been shown to play a central role in vivo in donor-specific blood transfusion-induced tolerance (3) and anti-ICOS-treated mice (4). Furthermore, we have shown in rats that blockade of CD40-CD40L interactions with CD40Ig-induced tolerogenic CD8 + CD45RC low Tregs, which generated infectious tolerance upon adoptive transfer (5). CD8 + CD45RC low Tregs produced IFN-g, and tolerance was dependent on both IFN-g and IDO (5). In human transplantation studies, CD8 + Tregs have not only been described in kidney (6)-, heart (7, 8)-, and liver-intestine (9)-transplanted patients but also associated with less rejection episodes (7, 8) and even tolerance (6). Although these observations highlight an important role of CD8 + Tregs in allograft tolerance, there is a little information about the cellular interactions and anatomical sites associated with their generation, migration, and tolerogenic properties. CD4 + and CD8 + Treg (1, 2) function can be modulated by conventional dendritic cells (cDCs) and plasmacytoid DCs (pDCs). pDCs were shown to induce CD8 + Tregs in humans (6, 10, 11), mice, and rats (12-14). In a mouse cardiac transplantation model, pDCs were reported to induce tolerance by inducing CD4 + CD25 + Tregs in lymph nodes (LNs), and the migration of pDCs to LNs was crucial to induce tolerance (13).Obviously, different DC subsets and their migration profiles may exert different influences in the development of CD8 + Tregs and their regulatory function. The in vivo outcome of DCs and Tregs encounters depends also on the effects of CD4 + effector cells which potentiate and modify the suppressive mechanisms of CD4 + Tregs (15). This observation introduces an important new concept on the suppressive mechanisms of Tregs, indicating that it is not only bidirectional regulation with DC subsets, but rather a triangle modulation in which T effector cells (Teffs) play also a key role potentiating Treg function.
A lthough CD4 + regulatory T cells (Tregs) have received considerably more attention (1), CD8 + Tregs have been identified both as naturally occurring cells and after different immunotherapy regimen in various pathophysiological situations (2) . In organ transplantation, CD8
+ Tregs have been shown to play a central role in vivo in donor-specific blood transfusion-induced tolerance (3) and anti-ICOS-treated mice (4) . Furthermore, we have shown in rats that blockade of CD40-CD40L interactions with CD40Ig-induced tolerogenic CD8 + CD45RC low Tregs, which generated infectious tolerance upon adoptive transfer (5) . CD8 + CD45RC low Tregs produced IFN-g, and tolerance was dependent on both IFN-g and IDO (5) . In human transplantation studies, CD8 + Tregs have not only been described in kidney (6)-, heart (7, 8)-, and liver-intestine (9)-transplanted patients but also associated with less rejection episodes (7, 8) and even tolerance (6) . Although these observations highlight an important role of CD8 + Tregs in allograft tolerance, there is a little information about the cellular interactions and anatomical sites associated with their generation, migration, and tolerogenic properties. CD4 + and CD8 + Treg (1, 2) function can be modulated by conventional dendritic cells (cDCs) and plasmacytoid DCs (pDCs). pDCs were shown to induce CD8 + Tregs in humans (6, 10, 11) , mice, and rats (12) (13) (14) . In a mouse cardiac transplantation model, pDCs were reported to induce tolerance by inducing CD4 + CD25
+ Tregs in lymph nodes (LNs), and the migration of pDCs to LNs was crucial to induce tolerance (13) .Obviously, different DC subsets and their migration profiles may exert different influences in the development of CD8 + Tregs and their regulatory function. The in vivo outcome of DCs and Tregs encounters depends also on the effects of CD4 + effector cells which potentiate and modify the suppressive mechanisms of CD4 + Tregs (15) . This observation introduces an important new concept on the suppressive mechanisms of Tregs, indicating that it is not only bidirectional regulation with DC subsets, but rather a triangle modulation in which T effector cells (Teffs) play also a key role potentiating Treg function.
In the current study, using a model of transplantation tolerance mediated by CD8 + Tregs following CD40Ig treatment in rats (5), we found that tolerance induction was associated with an accumulation of CD8 + CD45RC low cells first in the graft and then in the spleen but not in LNs. The splenic compartment appeared to be sufficient at early time points and necessary at late time points for the induction and maintenance of tolerance. pDCs accumulated in the graft and spleen of tolerant animals and preferentially *Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 643; supported the regulation of alloreactive CD4 + T cells by CD8 + CD45RC low cells in vitro. Finally, we uncovered complex interactions between effector CD4 + T cells, pDCs, and CD8 + Tregs that resulted in distinct regulatory mechanisms depending on the extent of cell-cell contacts between the different cell populations.
Materials and Methods

Animals and cardiac transplantation models
Heart allotransplantation was performed between whole MHCincompatible male LEW-1W (donors) and LEW-1A (recipients) rats as described previously (5) . The experiments complied with the Institutional Ethical Guidelines of the Institut National de la Santé et de la Recherche Médicale (Nantes, France).
Adenovirus-mediated gene transfer and mAb administration
The recombinant noncoding adenovirus (Ad) Addl324 and the Ad encoding for the extracellular portion of mouse CD40 fused to the constant domains of human IgG1 (AdCD40Ig) with the mouse CMV promoter as well as the procedure of intragraft delivery have been described previously (5) .
A neutralizing mouse anti-rat IFN-g mAb (DB1, IgG1; provided by P. H. Van der Meisle, Amsterdam, The Netherlands) or the isotype control 3G8 mAb was injected (3 mg/kg) i.p. twice a week beginning the day of transplantation. The IDO-specific inhibitor, 1-methyltryptophan, was administered twice daily by oral gavages at 50 mg/dose, as described previously (5) . A neutralizing murine anti-TGF-b mAb (2G7; provided by Dr. K. Melief, Amsterdam, The Netherlands) was injected i.p (5 mg/kg) twice a week beginning the day of transplantation as described previously (16). All treatments were continued until rejection or 40 d.
Adoptive transfer
Naive LEW-1A recipients received 4.5 Gy whole-body irradiation on the day before transplantation. Total splenocytes, bone marrow (BM) cells, LNs, or PBLs (50-100 3 10 6 cells) as well as PKH-labeled pDCs (1.5 3 10 6 cells) or PKH-labeled CD8 + Tregs (2.5 3 10 6 cells) were adoptively transferred into recipients i.v. immediately after allograft implantation.
Purification of T cell subpopulations
T cells were enriched by negative selection from total splenocytes after depletion with a mixture of mAbs reactive with gdT cells (V65), B cells (His24, anti-CD45R), NK cells (3.2.3, anti-CD161), and monocytes (OX42, anti-CD11b/c) and magnetic beads (Dynal Biotech, Cergy Pontoise, France). Enriched T cells were labeled with a mixture of anti-CD45RC-biotin (OX22), anti-CD8a-PE (OX8), anti-CD6-FITC (OX56), anti-CD25-Alexa647 (OX39), and strepavidin-PE-Cy7. CD8 
Purification of DC subsets
DCs subsets were prepared and isolated from spleen as described previously (17, 18). Briefly, spleens were digested by collagenase D, followed by Nycodenz gradient centrifugation and the middle layer of cells was collected as enriched cDCs. cDCs were sorted using the following Abs: anti-TCR (R73-FITC), anti-CD45RA (OX33-FITC), CD103 (OX62-APC), and anti-CD4 (OX35-PE). cDCs were defined as TCR 2 CD45RA 2 CD103 + cells and further sorted into CD4 + cDCs and CD4 2 cDCs subpopulations (17). The Nycodenz cell pellet was fractioned by Ficoll-Hypaque gradient centrifugation, and middle layer cells were depleted of T cells (R73 and V65 clones) and B (OX33 clone) cells, followed by sorting of pDCs using the following Abs: anti-TCR (R73-FITC), anti-CD45RA (OX33-FITC), CD45R (His24-PE), and anti-CD4 (OX35-APC). pDCs were defined as TCR 2 CD45RA
2
CD45R
+ CD4 + cells (18). Cell sorting was performed with a FACSAria with cell purity of sorted populations .98%.
mAbs and flow cytometry
The Abs used for sorting CD8 + T cells and DC subsets were obtained from the European Collection of Cell Culture (Salisbury, U.K.). All biotin-labeled mAbs were visualized using strepavidin-PE-Cy7 (BD Biosciences). Fibroleukin-2 (Fgl-2) was detected using a murine mAbs anti-Fgl-2 (Abnova, Heidelberg, Germany), An LSR II cytometer (BD Biosciences) was used to measure fluorescence, and data were analyzed using the FlowJo software (Tree Star, Ashland, OR). Cells were first gated by their morphology excluding dead cells, and the gates that were used to separate the populations and the percentages of gated cells are depicted in Supplemental Fig. 1 . (20 or 100 mg/ml), rabbit anti-rat IL-10 (19) (20 mg/ml, provided by Dr. J. Khalife, Institut Pasteur de Lille, France), murine anti-TGF-b mAb (20 mg/ml), the IDOspecific inhibitor methyl-thiohydantoin-tryptophan (MTHT; 20 mM) (Calbiochem, Nottingham, U.K.) (20) , B18R from vaccinia virus neutralizing all type I IFNs (21) (eBioscience, San Diego, CA) (250 pg/ml or 2 ng/ml), or an anti-Fgl-2 mAb (20 mg/ml). IFN-g was measured using ELISA kits (BD Biosciences).
Mixed leukocyte reaction
Ag presentation by indirect pathway
Heart resident leukocytes were isolated from donor LEW.1W hearts digested with collagenase D, followed by Ficoll gradient centrifugation. Apoptosis was induced by UV irradiation (TUV 30 W/G 30 TB; wavelength 280-340 nm; Philips, Eindhoven, The Netherlands) for 3 h at room temperature. Apoptotic cells were then cultured overnight with recipient (LEW.1A) DC subsets (1:1 ratio) at 10 6 pDCs/ml. Ficoll gradient centrifugation was used to harvest DCs loaded with donor alloantigens and eliminated apoptotic cells.
Histological analysis and microscopy
Cryostat sections were harvested and fixed in acetone. Sections were mounted in Prolong Antifade Kit (Molecular Probes, Invitrogen, Cergy Pontoise, France) and analyzed by confocal microscopy (Leica TCS-SPE, Nanterre, France) with ImageJ software (National Institutes of Health, Bethesda, MD).
Fgl-2 quantitative RT-PCR
The isolation and retrotranscription of mRNA as well as the quantification of specific mRNA levels using SYBR green technology after normalization to hypoxanthine phosphoribosyltransferase values have been described previously (5) . The sequence of primer pairs for rat Fgl-2 was 59-CAAGA-ACACAACCAGCCAAATCC-39 (forward) and 59-CCCAGCCAAAATT-CTCGTTCAA-39 (reverse).
Statistics
For graft survival, log-rank test was done. For numbers of DC subsets and proliferation assay, ANOVA test was done to examine individual differences versus various controls. For CD8 + CD45RC low T cell percentages, one-way ANOVA was done.
Results
Tolerogenic CD8
+ Tregs sequentially accumulate in the allograft and the spleen Treatment of graft recipients with AdCD40Ig resulted in long-term cardiac allograft survival (5) . Tolerance to cardiac allografts induced by CD40Ig treatment could be adoptively transferred exclusively by CD8 + CD45RC low Tregs, whereas CD8 + CD45RC low T cells from naive animals failed to do so (5). Thus, CD8 + CD45RC low cells from naive animals versus tolerant CD40Ig-treated transplanted recipients will be hereafter referred to as natural (or naive) versus tolerogenic CD8 + Tregs, respectively. In previous work and in the present paper, adoptive transfers were performed with recipient cells isolated at different time after CD40Ig treatment and transferred to graft recipients sublethally irradiated the day before transplantation. Tolerance was induced in 50% of recipients that were transferred with splenocytes harvested after 1 wk of treatment, and this frequency was increased to 100% when splenocytes were harvested 1 or 3 mo after treatment (Fig.  1A) . In contrast, graft survival was not prolonged after adoptive transfer of the same numbers (Fig. 1B) or even double numbers (data not shown) of LN cells. To examine the role of cells present within the allograft in the prevention of rejection, tolerant allografts were retransplanted into naive recipients without CD40Ig treatment. Even though they were eventually rejected in ,45 d, retransplanted allografts survived significantly longer than primary allografts (Fig. 1C) .
The data above suggested that CD8 + Tregs present in both spleen and allograft could contribute to graft acceptance. The presence of CD8 + CD45RC low T cells was thus analyzed in the spleen, LN, and allograft at 1 wk, 1 mo, and 3 mo after treatment with CD40Ig. Tolerogenic CD8 + Tregs appeared firstly in the allograft (1 wk) and later in the spleen (1 mo) but never in LNs (Fig.  1D ). One week after CD40Ig treatment, the proportion of tolerogenic CD8
+ Tregs increased rapidly in the allograft and then remained stable, whereas it took 3 mo to reach similar levels in the spleen (Fig. 1E ). Control animals treated with Addl324 virus showed lower proportion of CD8 + CD45RC low cells in the spleen at 3 mo after transplantation, comparable to that of naive animals (data not shown). To further investigate whether the organ distribution of CD8 + Tregs correlated with their tolerogenic properties, PKH-labeled natural or tolerogenic CD8 + Tregs were adoptively transferred into recipients immediately after transplantation. Tolerogenic CD8 + Tregs migrated to the cardiac graft within 5 d, whereas natural CD8 + Tregs did not (Fig. 1F) . A higher proportion of tolerogenic CD8 + Tregs was observed in the spleen compared with natural CD8 + Tregs and little to none tolerogenic or natural CD8 + Tregs were observed in LNs (Fig. 1F) or the recipient native heart (data not shown). Thus, long-term allograft survival was associated with accumulation of tolerogenic CD8 + Tregs first in the allograft and later in the spleen.
The spleen is dispensable for the generation but necessary for the long-term maintenance of tolerogenic CD8 + Tregs
To investigate the role of the spleen in the development of tolerogenic CD8 + Tregs, we treated graft recipients with a suboptimal dose of CD40Ig to induce tolerance in ∼50% of recipients. Splenectomy performed on the day of transplantation together with a suboptimal dose of CD40Ig treatment increased allograft survival rates to 100%, whereas splenectomy alone did not alter allograft survival ( Fig. 2A) . Splenectomy 3 mo after treatment did not abrogate long-term allograft survival (Fig. 2B ). In contrast, allografts were rejected when the spleen was removed 6 mo after CD40Ig treatment (Fig. 2B ). These very contrasted data following splenectomy suggest that although tolerogenic CD8
+ Tregs were present in the spleen at earlier time points after transplantation (= 3 mo), their removal was dispensable for maintaining tolerance suggesting the presence of CD8 + Tregs in other organ compartments. Furthermore, because splenic tolerogenic CD8 + Tregs can transfer tolerance while removal of spleen on day 0 improved the survival of allografts, both rejection and tolerance mechanisms occurred simultaneously in the spleen.
We examined the anatomic location of tolerogenic CD8 + Tregs in splenectomized recipients with long-term surviving allografts. Adoptive transfer of LN cells, PBLs, and BM cells from splenectomized tolerant recipients was performed. Partial but significant prolongation of allograft survival was observed only with the transfer of BM cells (Fig. 2C) . In contrast, adoptive transfer of BM cells from CD40Ig-treated rats with an intact spleen did not prolong allograft survival (Fig. 2C) . Furthermore, in splenectomized recipients with long-term surviving grafts, an expansion of CD8 + CD45RC low T cells was observed in the BM, but not in LN and peripheral blood, whereas CD8 + CD45RC low Tregs were present at a much lower frequency in the BM of CD40Ig-treated animals (Fig. 2D ) or naive rats (data not shown). These data suggest that, in splenectomized animals, the BM could substitute for the spleen as a reservoir of tolerogenic CD8 + Tregs. Thymus was also dispensable to generate the tolerogenic mechanism because tolerance was induced in all recipients after thymectomy at the day of transplantation (Supplemental Fig. 2 ) and could be adoptively transferred to naive recipient by splenocytes from thymectomized animals (data not shown).
Differential accumulation of pDCs in the spleen and allograft in tolerant versus rejecting recipients
The number of cells in different DC subsets was compared in the spleen of recipients that rejected or tolerated allografts. Numbers of pDCs were mostly stable in tolerant spleen, although they slightly increased 3 mo after transplantation. In contrast, numbers of pDCs in rejected spleen were dramatically decreased in the early phase (rejection occurred between 6 and 9 d), reaching less than half at 2 wk and recovering after 3 mo (Fig. 3A) . Numbers of CD4 2 cDCs in tolerant spleen increased in the first week, remained high at 2 wk, and decreased to pretransplantation levels by 3 mo (Fig.  3B ). The numbers of CD4 2 cDCs in rejected spleen also increased in the first week and then decreased rapidly to pretransplantation levels by 2 wk. The changes in numbers of CD4 + cDCs were similar in rejected and tolerant spleens, increasing during the first week, and stably returning to pretransplantation levels after 2 wk (Fig. 3C) . Thus, although changes in numbers of splenic CD4 2 cDCs and CD4 + cDCs were associated temporally with the early inflammatory response in both rejecting and tolerant recipients, pDCs were the only DC subset characterized by dynamic changes that correlated with the outcome of the allograft.
The presence of pDCs was analyzed in the LN and allograft 5 d after transplantation. The percentage of pDCs in LNs was similar in rejecting and tolerant recipients (Fig. 3D) . In contrast, in the graft, pDCs were observed in higher percentages in tolerant allografts versus rejected allografts (Fig. 3D) and were also present in longsurviving allografts (data not shown) suggesting that the preferential migration of pDCs to long-term surviving allografts was important to prevent acute rejection and induce tolerance. cDCs populations in LNs were not different in the experimental groups at day 5 after transplantation, and it was not possible to identify them using the conditions used in lymphoid organs, probably because of inflammatory and necrotic cells during acute rejection (data not shown).
Because numbers of pDCs in tissues correlated with induction of tolerance by CD40Ig, we examined the relationship between pDCs and tolerogenic CD8 + Tregs that mediate this tolerant state (5). The presence and accumulation of pDCs were analyzed in vivo by tracing PKH-labeled naive pDCs from recipient origin adoptively transferred simultaneously with natural or tolerogenic CD8 + Tregs, and animals were sacrificed at day 5. The use of recipient pDCs aimed to reproduce the changes observed in the distribution of pDCs described above and also on the fact that recipient pDCs were able to present donor Ags to CD8 + Tregs and trigger suppression (see next section). The use of natural or tolerogenic CD8 + Tregs Fig. 1 ) in LNs and allografts at day 5 after transplantation in syngeneic, rejected, or tolerant recipients. Data are representative of three independent experiments. The accumulation of pDCs was evaluated by adoptive cell transfer experiments using PKH-labeled cells (E-G). E, PKH-labeled pDCs were adoptively transferred in along with CFSE-labeled natural or tolerogenic CD8 + Tregs to mimic rejection or longterm allograft survival conditions (samples labeled rejected and tolerated, respectively). The samples were collected on day 5 and analyzed by confocal microscopy or cytofluorimetry. The spleens were analyzed by confocal microscopy (upper panels, original magnification 363; lower panels were digitally amplified to original magnification 3200). CD8 + Tregs are green, and pDCs are red. Data representative of three independent experiments and in each spleen at least five sections were analyzed. F, The numbers of PKH-positive pDCs in spleen and allograft were presented as cells per field. At least two sections were counted for each sample and at least six independent fields were analyzed for each section. ppp = 0.0006 for tolerant spleen versus rejected spleen; ppp = 0.008 for tolerant allograft versus rejected allograft. G, After gating TCR aimed to mimic the outcome of the graft, rejection or tolerance, but the early timing of sacrifice was necessary to analyze the fate of this cells within the graft before complete rejection (∼ day 7).
PKH-labeled pDCs in spleens were more frequently juxtaposed to CFSE-labeled tolerogenic CD8 + Tregs compared with natural CD8 + Tregs (Fig. 3E) . The numbers of CFSE-labeled tolerogenic CD8 + Tregs were higher versus natural CD8 + Tregs in the spleen (608 6 11 versus 365 6 13 CFSE + cells/section; n = 12; p , 0.05), and the percentage in contact with PKH-labeled pDCs was also higher with tolerogenic versus natural CD8 + Tregs (23.7 versus 10.4%, respectively; p , 0.05). Enumeration of PKH-labeled pDCs showed that numbers of pDCs were significantly higher in the spleen and graft when pDCs were cotransferred with tolerogenic compared with naive CD8 + Tregs (Fig. 3F) . Furthermore, PKH-labeled pDCs were not observed in LNs (data not shown). Cytofluorimetry analysis of PBMCs showed a significantly higher percentage of PKH + pDCs in recipients transferred with tolerogenic CD8
+ Tregs compared with naive CD8 + Tregs (Fig. 3G) . PKHlabeled pDCs were also observed in the BM of recipients transferred with tolerogenic or naive CD8 + Tregs without significant differences (data not shown). Thus, tissue accumulation of pDCs correlated with both graft outcome and localization of tolerogenic CD8 + Tregs, suggesting privileged interactions between the two cell subsets. in the presence of first-donor-and third-party-derived immature pDCs but tolerogenic CD8 + Tregs showed significantly higher suppression when using first donor-derived but not third-party pDCs (Fig. 4A) . The enhanced suppressive effect of tolerogenic CD8 + Tregs when using first-donor pDCs was dose dependent when analyzed both at the level of percentage of nonproliferating cells (Fig. 4B) and mean fluorescence intensity of proliferating cells (Fig. 4C) . When either of the two rat cDC populations (CD4 + or CD4 2 ) (17, 22) of first donor origin were used in the suppressive MLR assay, suppression of CD4 + T cell proliferation was induced by natural and tolerogenic CD8 + Tregs in the presence of CD4 2 cDCs, whereas no or little suppression was observed with CD4 + cDCs (Supplemental Fig. 3A-C) . Taken together, these results show that pDCs were the most effective DC subset to mediate donor specific suppression by tolerogenic CD8 + Tregs and that the suppression was higher when using first Fig. 4C, 4D) . These results demonstrate that rat pDCs can cross-present Ags as was previously observed in humans and mice (23) (Fig. 4D) . In the Transwell assay, we did not observe higher suppression by tolerogenic versus naive CD8 + Tregs, as we did in the coculture system, suggesting different suppressive mechanisms in each situation. However, tolerogenic CD8 + Tregs without direct contact with allogeneic pDCs in the upper chamber did not exert suppression of CD4 + effector T cells in the lower chamber (Fig. 4D) (Fig. 5A) . In contrast, although IFN-g can induce IDO (24), IFN-g http://www.jimmunol.org/ was not responsible for the contact-independent suppression of CD4 + T cells, because a neutralizing anti-IFN-g Ab did not reverse suppression (Fig. 5B) , and concentrations of IFN-g in the supernatant did not correlate with suppression (Fig. 5C) . These results also indicate that IDO-mediated suppression by CD8 + Tregs inhibited the proliferation but not the effector function of CD4 + T cells assessed by IFN-g production. Because IDO is also induced by type I IFNs (24), we tested the effect of the viral molecule B18R (which neutralizes all type I IFNs) (21) . Suppression was still observed in the presence of B18R (data not shown), indicating that production of IDO was controlled by IFN-independent mechanisms.
We examined whether the suppressive mechanisms of tolerogenic CD8 + Tregs could be modified after contact with CD4 + cells by analyzing the suppressive function of CD8 + Tregs in a coculture MLR containing CD8 + Tregs, pDCs, and CD4 + cells. Although tolerogenic CD8
+ Tregs suppressed CD4 + T cell proliferation as efficiently as in the Transwell system, the addition of neutralizing anti-IFN-g Ab abrogated the suppression by CD8 + Tregs in the coculture MLR (Fig. 5D) . In contrast, addition of soluble IFN-g protein alone did not suppress the proliferation of CD4 + CD25
2
T cells (Fig. 5D) . Furthermore, the addition of tolerogenic CD8 + Tregs to the coculture system significantly suppressed the production of IFN-g ( (Fig. 5F ). Thus, contacts with CD4 + T cells modified the suppressive mechanisms of CD8 + Tregs to an IFN-g-dependent mechanism, different from the IDO-dependent mechanism observed when cells were not in contact in the Transwell system.
Our previous in vivo data supports a role for both IDO-and IFNg-dependent mechanisms in allograft tolerance. We previously reported that both IDO and IFN-g were crucial in the maintenance phase of long-term allograft survival after adoptive transfer of CD8 + Tregs (5). We now further confirm that IDO and IFN-g are necessary in the induction phase of long-term allograft survival by CD40Ig treatment, because graft rejection was triggered after administration at the day of transplantation of an IDO inhibitor in 60% of recipients (Supplemental Fig. 5A ) and in 75% of recipients after administration of an anti-IFN-g Ab (Supplemental Fig. 5B ).
Fgl-2 is involved in suppression when CD8
+ Tregs are in contact with CD4 + T cells
To identify other mediators potentially involved in suppression by CD8 + Tregs, we performed microarray analysis to compare tolerogenic versus naive CD8 + Tregs from spleen from recipients of long-surviving allografts (.100 d) and naive animals and showed increased expression of several potentially regulatory molecules in tolerogenic CD8 + Tregs. Among them was Fgl-2, which has been shown to have suppressive functions on CD4 + effector T cells through action on DCs (25) . We confirmed that Fgl-2 expression was significantly increased in tolerogenic compared with naive CD8 + Tregs by quantitative RT-PCR (Fig. 6A ) and at protein level at the membrane of cells by FACS analysis (Fig. 6B) and by confocal microscopy within the cells (Fig. 6C) . Importantly, inclusion of a neutralizing anti-Fgl-2 Ab restored CD4 + T cell proliferation in the coculture MLR suppression assay (Fig. 6D) . These results suggest that Fgl-2, a molecule induced by IFN-g (25) , was one of the mediators of CD8 + Treg suppression when CD4 + and CD8 + Tregs were in contact. Altogether, although both IFN-g-and IDO-dependent mechanisms coexisted in vivo for tolerance induction by tolerogenic CD8 + Tregs, these pathways occurred independently and differentially depending on cell contacts with CD4 + T cells, which switched suppression from an IDO-dependent mechanism in the absence of contacts to an IFN-g-and Fgl-2-dependent mechanism in the presence of contacts.
Discussion
In this model of vascularized heart transplantation in rats, we have defined the kinetics, tissue distribution, and cellular interactions underlying tolerance induction by CD8 + CD45RC
low Tregs following CD40Ig treatment. We demonstrate that the accumulation of tolerogenic CD8 + Tregs first occurs within the allograft, whereas maintenance of long-term tolerance requires the splenic compartment. pDCs appear to play a predominant role in the tolerogenic process as their dynamics correlate with both allograft outcome and tissue distribution of tolerogenic CD8 + Tregs in vivo, and they preferentially induce Tregs suppression in vitro. Distinct mechanisms of suppression occurred depending on cellular interactions taking place in the MLR in vitro. In particular, the presence or absence of contacts between CD8 + Tregs and CD4 + Teffs resulted in a switch between an IFN-g-and Fgl-2-dependent mechanism and an IDO-dependent mechanism of suppression, respectively. Because both IFN-g and IDO are important for tolerance mediated by CD8 + CD45RC low Tregs in vivo (5), these results suggest that CD8 + Tregs suppress alloreactive CD4 + responses by both contact-dependent and -independent mechanisms after CD40Ig treatment. The spleen was dominant among lymphoid organs to generate and maintain tolerogenic CD8 + Tregs because tolerance could be transferred with splenocytes early after transplantation and rejection occurred upon splenectomy long-term after transplantation. Alloantigen priming from vascularized organs has been shown to occur both in the spleen and the LN (26) . In a rat heart allotransplantation model similar to ours (27) , blood was the preferential route for migration of recipient DCs into the graft and later for both donor and recipient DC migration into the spleen with no migration into regional LNs. This is opposed to islets grafted under the kidney capsule where lymphatic drainage is largely predominant. In our model, at early time points, spleen could be partially replaced by BM, which contained CD8 + Tregs and prolonged allograft survival upon transfer. BM is part of the lymphocyte recirculation pool, and CD4 + CD25
+ Tregs can accumulate in the BM (28) . Our results showing accumulation of tolerogenic CD8 + Tregs first in the graft and later in the spleen are concordant with a recent model of islet transplantation where CD4 + Tregs first transit to the graft before migrating to lymphoid organs (29) . CD8 + Tregs have also been shown to accumulate in tumor sites (11) , allografts (4), or inflamed lymphoid tissue (30) . The observation that transferred tolerogenic CD8 + Tregs were found in higher numbers in the graft and spleen compared with natural CD8 + Tregs may represent increased migration, as previously observed for CD4 + Tregs (29) . In this regard, a pangenomic microarray analysis showed an increase (fold increase versus naive CD8 + Tregs) of several molecules, which could explain different migratory profiles, such as CXCR3 (2.55), CCR5 (9.63), CCR2 (6.6), and CCL5 (4.75), that were confirmed by quantitative RT-PCR (data not shown).
In tolerant animals, transferred pDCs accumulated in the graft, spleen, blood, and BM but not in LNs, and this distribution is concordant with the preferential hematogenous route for pDC migration (31) . In contrast, during rejection, numbers of pDCs in the spleen decreased dramatically. The intragraft accumulation of pDCs in CD40Ig-treated recipients is reminiscent of tolerance (anti-CD40L plus donor-specific blood transfusion) in a cardiac graft model in mice (13) , but pDC migration differed between the two models because tolerance was associated with accumulation of pDCs to LNs in the mouse model and to the spleen in our model. Furthermore, in this mouse model, tolerance was associated with CD4 + CD25 + Tregs (13) . These differences may be explained by the use of distinct species and tolerance protocols. The suppressive function of CD8 + Tregs was observed in the presence of pDCs and CD4 2 cDCs but not CD4 + cDCs, so we cannot exclude a role for CD4 2 cDCs in tolerance induction in our model. Nevertheless, donor-specific suppression was only mediated by pDCs. CD8 + Tregs displayed donor alloantigen recognition in both direct and indirect Ag presentation pathways. CD4 + CD25
+ Tregs with both specificities are more efficient to inhibit allograft rejection (32) , suggesting that both pathways could participate in suppression by CD8 + Tregs.
The tolerance induced by CD8 + Tregs in our model could be explained by the action of Tregs on DCs (1), as previously reported for CD4 + Tregs (33, 34) and CD8 + Tregs (7, 35) . Conversely, pDCs can induce allospecific CD8 + Tregs (6, 11) and CD4 + Tregs through mechanisms, such as IDO (12) . IDO exists as two isoforms, IDO1 and IDO2 (36, 37) , and although IDO1 was expressed by pDCs (data not shown), the expression of IDO2 and, more importantly the function of IDO1 and/or IDO2 in pDCs in this model, requires further research. Contact with pDCs was necessary to trigger suppression by tolerogenic CD8 + Tregs in our model. Although CTLA4 (33, 34) or the programmed death-1 (PD-1) ligand (4) in coculture MLR. Fgl-2 is a membrane and/or secreted molecule induced by IFN-g and produced by CD4 + CD25 + Tregs (38) and TCR + CD8 + aa intraepithelial lymphocytes (39) . Fgl-2 has been reported to inhibit T cell proliferation and DC maturation (25) through binding to T cells (25) + Tregs have been shown to exert suppression through contact-dependent (7, 35, 41, 42) or -independent mechanisms (4, 43). Contact-dependent mechanisms include cytotoxicity (41) but not TGF-b (7, 35, 42) or IL-10 (7). Contact-independent mechanisms can involve IFN-g (43) , TGF-b (43), and PD-1 (4) but not IL-10 (44). Donorspecific cytotoxicity was reduced in CD40Ig-treated recipients (5) . The inclusion of IL-10-or TGF-b-neutralizing Abs in coculture or Transwell MLR did not modify suppression and long-term allograft survival was unchanged by anti-TGF-b Ab administration (data not shown).
Despite its recognized effects promoting immune responses, IFN-g also has tolerogenic effects (45) . IFN-g upregulates Foxp3 expression in CD4 + CD25 + Tregs (46) , and it has been implicated in suppression mediated by CD8 + Tregs (43, (47) (48) (49) . In a model of CD137 costimulation blockade, inhibition of immune responses was dependent on IFN-g, yet IFN-g alone did not induce suppression and acted through induction of TGF-b production by CD8 + Tregs (43) . Similarly, in another model of CD8 + Tregs, IFN-g did not directly inhibit CD4 + responses but rather licensed CD8 + Tregs to inhibit these responses (49) . IFN-g has been shown to induce a weak and transient increase of IDO functional activity in DCs, but neutralization of IFN-g or IFN type I with B18R did not completely reverse IDO-dependent suppression, suggesting additional mechanisms inducing IDO, such as ligation of CD200, TLRs, or TNF-a and PGE 2 (24, 34) . In our model, IFN-g could be tolerogenic by inducing Fgl-2 on CD8 + Tregs. The involvement of IFN-g only when CD4
+ cells were in contact with DCs and Tregs could be explained by the directional secretion of IFN-g to cells in close contact rather than diffuse production (50) . Although IFN-g promotes IDO expression on allografts (5) and allografts from IFN-g-deficient donors are rejected more rapidly than wild-type grafts (51) , intracoronary infusion of IFN-g caused accelerated acute rejection in large animals (52), indicating that the effects of IFN-g must take place both in the graft and in the lymphoid organs where close contact between CD4 + , CD8 + Tregs, and DCs occur.
DC-T cell interaction in the absence of CD40L-CD40 results in cross-tolerization of CD8 + T cells, and IDO was shown to be essential (53) . We found that IFN-g was not responsible for IDO activity in vitro and other potential molecules that could induce IDO, such as IFN-I, TGF-b, and CTLA4 (33, 34) , were also excluded. Further work is thus needed to identify the mechanism by which tolerogenic CD8 + Tregs induce IDO activity. In conclusion, our results suggest that migration of pDCs and CD8 + Tregs to the graft and spleen allowed in vivo interactions necessary for suppression of CD4 + T cells. This suppression involved different mechanisms modulated by the presence of cell contact with CD4 + T cells, and IDO, IFN-g, and Fgl-2 were the main mediators in vitro. In vivo, IDO and IFN-g were essential for long-term allograft survival, suggesting that alloreactive CD4 + Teffs are suppressed by tolerogenic CD8 + Tregs through both contact-dependent and -independent mechanisms. 
